aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
Company profile
Ticker
AIM
Exchange
Website
CEO
Thomas Equels
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HEMISPHERX BIOPHARMA INC
SEC CIK
Corporate docs
Subsidiaries
BioPro Corp. • BioAegean Corp. • Hemispherx Biopharma Europe ...
IRS number
520845822
AIM stock data
Latest filings (excl ownership)
D/A
$3.30 mm in debt, sold $3.30 mm, 1 investor
21 Feb 24
D
Exempt offering of security
20 Feb 24
8-K
Entry into a Material Definitive Agreement
20 Feb 24
8-K
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
9 Feb 24
8-K
Regulation FD Disclosure
25 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
10 Jan 24
8-K
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating
10 Jan 24
DFAN14A
Additional proxy materials by non-management
3 Jan 24
DEFA14A
Additional proxy soliciting materials
29 Dec 23
DEFA14A
Additional proxy soliciting materials
28 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.26 mm | 15.26 mm | 15.26 mm | 15.26 mm | 15.26 mm | 15.26 mm |
Cash burn (monthly) | 1.92 mm | 1.21 mm | 2.72 mm | 1.96 mm | 1.89 mm | 1.46 mm |
Cash used (since last report) | 11.51 mm | 7.22 mm | 16.25 mm | 11.69 mm | 11.30 mm | 8.76 mm |
Cash remaining | 3.76 mm | 8.04 mm | -990.53 k | 3.57 mm | 3.96 mm | 6.51 mm |
Runway (months of cash) | 2.0 | 6.7 | -0.4 | 1.8 | 2.1 | 4.4 |
Institutional ownership, Q2 2023
9.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 5 |
Closed positions | 7 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 2.86 bn |
Total shares | 4.49 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.99 mm | $1.33 bn |
BLK Blackrock | 707.54 k | $474.05 mm |
MS Morgan Stanley | 435.56 k | $291.82 mm |
Geode Capital Management | 380.91 k | $255.21 mm |
Renaissance Technologies | 178.81 k | $120.00 k |
STT State Street | 173.10 k | $115.98 mm |
Verition Fund Management | 140.00 k | $93.80 mm |
Bridgeway Capital Management | 108.90 k | $72.96 mm |
NTRS Northern Trust | 86.52 k | $57.97 mm |
Susquehanna International | 54.61 k | $36.59 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Nancy Bryan | Common Stock | Buy | Acquire P | No | No | 0.39 | 38,462 | 15.00 k | 38,462 |
15 Mar 24 | Stewart Appelrouth | Common Stock | Buy | Acquire P | No | No | 0.33 | 90,910 | 30.00 k | 239,765 |
15 Mar 24 | Iii Peter W. Rodino | Common Stock | Buy | Acquire P | No | No | 0.33 | 37,879 | 12.50 k | 181,718 |
15 Mar 24 | Equels Thomas K. | Common Stock | Buy | Acquire P | No | No | 0.33 | 75,758 | 25.00 k | 716,455 |
30 Nov 23 | Equels Thomas K. | Options Common Stock | Grant | Acquire A | No | No | 0.47 | 300,000 | 141.00 k | 300,000 |
News
Earnings Scheduled For March 26, 2024
26 Mar 24
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
25 Mar 24
AIM ImmunoTech Launches CEO Corner Platform
7 Mar 24
AIM ImmunoTech Announces First Subject Dosed In Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca's Imfinzi For Pancreatic Cancer
14 Feb 24
12 Health Care Stocks Moving In Monday's After-Market Session
12 Feb 24
Press releases
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
28 Mar 24
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
26 Mar 24
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
25 Mar 24
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
22 Mar 24
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
20 Mar 24